Multiple myeloma patients receiving bortezomib, thalidomide and DEX with or without the anti‐CD38 monoclonal antibody, daratumumab, had no changes in DC populations in the absence of daratumumab during 12 weeks of treatment.17 This evidence concerns the gene CD38 and AL amyloidosis.